Home › Compare › IUGNF vs BTI

IUGNF vs BTI: Dividend Comparison 2026

IUGNF yields 1788.91% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IUGNF wins by $3531675981.97M in total portfolio value
10 years
IUGNF
IUGNF
● Live price
1788.91%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3531675982.01M
Annual income
$3,181,793,952,650,469.00
Full IUGNF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — IUGNF vs BTI

📍 IUGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIUGNFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IUGNF + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IUGNF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IUGNF
Annual income on $10K today (after 15% tax)
$152,057.25/yr
After 10yr DRIP, annual income (after tax)
$2,704,524,859,752,898.50/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, IUGNF beats the other by $2,704,524,859,750,530.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IUGNF + BTI for your $10,000?

IUGNF: 50%BTI: 50%
100% BTI50/50100% IUGNF
Portfolio after 10yr
$1765837991.02M
Annual income
$1,590,896,976,326,627.80/yr
Blended yield
90.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

IUGNF
No analyst data
Altman Z
-15.4
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IUGNF buys
0
BTI buys
0
No recent congressional trades found for IUGNF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIUGNFBTI
Forward yield1788.91% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$3531675982.01M ✓$37.7K
Annual income after 10y$3,181,793,952,650,469.00 ✓$2,786.64
Total dividends collected$3506616114.25M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IUGNF vs BTI ($10,000, DRIP)

YearIUGNF PortfolioIUGNF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$189,591$178,890.88$11,299$598.92+$178.3K → IUGNF
2$3,372,589$3,169,726.93$12,794$703.91+$3.36M → IUGNF
3$56,305,450$52,696,779.78$14,518$829.07+$56.29M → IUGNF
4$882,465,426$822,218,594.62$16,513$978.64+$882.45M → IUGNF
5$12,987,684,313$12,043,446,306.47$18,827$1,157.84+$12987.67M → IUGNF
6$179,550,479,073$165,653,656,858.63$21,518$1,373.12+$179550.46M → IUGNF
7$2,332,406,409,977$2,140,287,397,368.80$24,657$1,632.46+$2332406.39M → IUGNF
8$28,479,672,886,997$25,983,998,028,321.59$28,329$1,945.74+$28479672.86M → IUGNF
9$326,992,550,798,860$296,519,300,809,773.56$32,637$2,325.33+$326992550.77M → IUGNF
10$3,531,675,982,005,250$3,181,793,952,650,469.00$37,708$2,786.64+$3531675981.97M → IUGNF

IUGNF vs BTI: Complete Analysis 2026

IUGNF — Stock

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Full IUGNF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this IUGNF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IUGNF vs SCHDIUGNF vs JEPIIUGNF vs OIUGNF vs KOIUGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.